Most Read Articles
Rachel Soon, 2 days ago

Gels utilizing Stichopus horrens (golden sea cucumber/gamat) extract show a similar efficacy to standard-of-care hydrogels for promoting wound healing, according to a prospective study.

6 days ago
Sleep difficulties are exacerbated in long-term survivors of childhood cancers, which may lead to persistent emotional distress, a new study has found.
Yesterday
Higher cancer symptom burden in elderly adults is associated with functional impairment, reports a recent study.
Jairia Dela Cruz, 4 days ago
Use of mirabegron in the treatment of men with overactive bladder (OAB) appears to effectively alleviate urgency and storage symptoms, but not reduce the frequency of micturition episodes, according to data from the MIRACLE study.

Concurrent radiotherapy/panitumumab safe, noninferior to concurrent cisplatin/radiotherapy

6 days ago

Radiotherapy in parallel with panitumumab use following induction chemotherapy and pelvic lymph node dissection appears to be well tolerated and is noninferior to the historical profile of concurrent radiotherapy and cisplatin, a study has shown.

Participants included patients with cT1-4N0-2M0 bladder cancer who were treated with pelvic lymph node dissection and four cycles of platinum-based induction chemotherapy followed by a 6 ½-week schedule of weekly panitumumab (2.5 mg/kg) and concurrent radiotherapy to the bladder (33 x 2 Gy).

Concurrent radiotherapy/panitumumab toxicity was compared to a historical control toxicity rate of concurrent cisplatin/radiotherapy (<35 percent of patients with grade 3–5 toxicity). Thirty-one patients were analysed. Secondary endpoints were complete remission at 3-month follow-up, bladder preservation rate, epidermal growth factor receptor (EGFR) expression and RAS mutational status.

Thirty-four of the 38 patients initially included were staged cN0, of which seven (21 percent) were up staged to pN+ after pelvic lymph node dissection. Of the 38 patients, 31 initiated concurrent radiotherapy/panitumumab.

Systemic or local grade 3–4 toxicity occurred in five patients (16 percent; 95 percent CI, 0–31) during concurrent radiotherapy/panitumumab. Four patients ceased treatment due to adverse events.

Twenty-nine of 31 patients (94 percent; 83–100) achieved complete remission. Four patients had local recurrence, for which three (10 percent) underwent salvage cystectomy, at a median follow-up of 34 months. Furthermore, two tumours had EGFR or RAS mutation, while 84 percent showed positive EGFR expression.

“The high complete remission and bladder preservation rates are promising and warrant further study,” the authors said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Rachel Soon, 2 days ago

Gels utilizing Stichopus horrens (golden sea cucumber/gamat) extract show a similar efficacy to standard-of-care hydrogels for promoting wound healing, according to a prospective study.

6 days ago
Sleep difficulties are exacerbated in long-term survivors of childhood cancers, which may lead to persistent emotional distress, a new study has found.
Yesterday
Higher cancer symptom burden in elderly adults is associated with functional impairment, reports a recent study.
Jairia Dela Cruz, 4 days ago
Use of mirabegron in the treatment of men with overactive bladder (OAB) appears to effectively alleviate urgency and storage symptoms, but not reduce the frequency of micturition episodes, according to data from the MIRACLE study.